Caris Life Sciences (CAI) Assets (2024 - 2026)

Caris Life Sciences (CAI) posted quarterly Assets of $1.2 billion for Q1 2026, up 3.26% quarter-over-quarter from $1.1 billion in Q4 2025.

Caris Life Sciences (CAI) Assets (2024 - 2026) Analysis & Trends

Caris Life Sciences' Assets history runs 3 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

In Q1 2026, Assets changed N/A year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (changed N/A YoY), while the FY2025 annual figure was $1.1 billion, up 227.48% from the prior year.
Assets for Q1 2026 stood at $1.2 billion, up from $1.1 billion in the prior quarter.
The five-year high for Assets was $1.2 billion in Q1 2026, with the low at $343.7 million in Q4 2024.
The 3-year median for Assets is $984.6 million (2025), against an average of $914.3 million.
Peak annual rise in Assets reached 227.48% in 2025, while the deepest fall reached 227.48% in 2025.
Caris Life Sciences' Assets stood at $343.7 million in 2024, then surged by 227.48% to $1.1 billion in 2025, then grew by 3.26% to $1.2 billion in 2026.
Business Quant data shows CAI's Assets at $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $984.6 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	27.42 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	41.73 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	10.03 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	4.32 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	9.18 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	15.59 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.82 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	5.56 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	2.10 Bn
10	Caris Life Sciences	6.16 Bn	5.37 Bn	182.38 Mn	1.23 Bn

Download Data